Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: A multicenter phase II study

Lung Cancer

Volumn 63, Issue 1, 2009, Pages 77-82

  Boukovinas, I ^a   Souglakos, J ^b   Hatzidaki, D ^b   Kakolyris, S ^b   Ziras, N ^c   Vamvakas, L ^b   Polyzos, A ^d   Geroyianni, A ^e   Agelidou, A ^e   Agelaki, S ^b   Kalbakis, K ^b   Kotsakis, A ^b   Mavroudis, D ^b   Georgoulias, V ^b  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c 1st Department of Medical Oncology   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

^e KAT HOSPITAL   (Greece)

Author keywords

Docetaxel; Elderly; Gemcitabine; Lung adenocarcinomas

Indexed keywords

DEXAMETHASONE; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADVANCED CANCER; AGED; ALLERGY; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLU LIKE SYNDROME; GERIATRIC PATIENT; HUMAN; INTERSTITIAL PNEUMONIA; LUNG ADENOCARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMATITIS; SURVIVAL RATE; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; VOMITING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 57649099543     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.04.006     Document Type: Article

References (39)

1. Weir H.K., Thun M.J., Hankey B.F., Ries L.A., Howe H.L., and Wingo P.A. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95 17 (2003) 1276-1299
2. Gridelli C., Perrone F., and Monfardini S. Lung cancer in the elderly. Eur J Cancer 33 (1997) 2313-2314
3. Hutchins L.F., Unger J.M., Crowley J., Coltman Jr. C.A., and Albain K.S. Underrepresentation of patients 65 years of age or older in cancer treatment trials. N Engl J Med 341 (1999) 20611-20617
4. Monfardini S., Sorio R., Boes G.H., Kaye S., and Serraino D. Entry and evaluation of elderly patients in European Organization for Research and Treatment of cancer (EORTC) new-drugs development studies. Cancer 76 (1995) 333-338
5. Hurria A., and Kris M.G. Management of lung cancer in older patients. CA Cancer J Clin 53 (2003) 325-341
6. Aapro M.S., Kohne C.H., Cohen H.J., and Extermann M. Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist 10 (2005) 198-204
7. Gridelli C., Langer C., Maione P., Rossi A., and Schild S.E. Lung cancer in the elderly. J Clin Oncol 25 (2007) 1898-1907
8. Souquet P.J., Chauvin F., Boissel J.P., Cellerino R., Cormier Y., Ganz P.A., et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 342 (1993) 19-21
9. Non-Small Cell Lung Cancer Co-operative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311 (1995) 899-909
10. Pujol J.-L., Barlesi F., and Daures J.-P. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer 51 (2006) 335-345
11. Georgoulias V., Papadakis E., Alexopoulos A., Tsiafaki X., Rapti A., Veslemes M., et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small cell lung cancer: a randomised multicentre trial. Lancet 357 (2001) 1478-1484
12. Kosmidis P., Mylonakis N., Nicolaides C., Kalophonos C., Samantas E., Boukovinas I., et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 20 (2002) 3578-3585
13. Gridelli C., Gallo C., Shepherd F.A., Illiano A., Piantedosi F., Robbiati S.F., et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21 (2003) 3025-3034
14. Alberola V., Camps C., Provencio M., Isla D., Rosell R., Vadell C., et al. Cisplatin plus gencitabine versus a cisplatin-based triplet versus non-platinum sequential doublets in advanced non-small cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 21 (2003) 3207-3213
15. Laack E., Dickgreber N., Muller T., Knuth A., Ben K.J., Lorenz C., et al. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine and cisplatin in the treatment of advanced non-small cell lung cancer: from the German and Suisse Lung Cancer Study Group. J Clin Oncol 22 (2004) 2348-2356
16. Smit E.F., van Meerbeeck J.P., Lianes P., Debruyne C., Legrand C., Schramel F., et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gencitabine in advanced non-small cell lung cancer: a phase III trial of the European Organization for research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21 (2003) 3909-3917
17. Georgoulias V., Ardavanis A., Tsiafaki X., Agelidou A., Mihalopoulou P., Anagnostopoulou O., et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small cell lung cancer: a phase III randomized trial. J Clin Oncol 23 (2005) 2937-2945
18. Gridelli C., Perrone F., Gallo C., Cigolari S., Rossi A., Piantedosi F., et al. Chemotherapy for elderly patients with advanced non-small cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly study (MILES) phase III randomized trial. J Natl Cancer Inst 95 (2003) 362-372
19. National Cancer Institute: Common Toxicity Criteria (CTC) v2.0. http://ctep.cancer.gov/reporting/ctc.html.
20. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
21. Freidlin B., Breathnach O.S., and Johnson B.E. A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer. Clin Cancer Res 9 (2003) 917-923
22. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
23. Cox D.R. Regression models and life tables. J R Stat Soc B 34 (1972) 187-220
24. Koo L.C., and Ho J.H.-C. Worldwide epidemiological patterns of lung cancer in not smokers. Int J Epidemiol 19 Suppl. 1 (1990) s14-s23
25. Scagliotti G., vonPawel P., Biesma J., Vansteenkiste B., Manegold J., Simms C., et al. Phase III study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Thor Oncol 2 August (8) (2007) [PRS-03 abstract]
26. The Elderly Lung Cancer Vinorelbine Italian Study group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 91 (1999) 66-72
27. Araya T., Kasahara K., Kimura H., Shibata K., Kita T., Shirasaki H., et al. Bi-weekly administration of gemcitabine plus vinorelbine in elderly patients with advanced non-small cell lung cancer: multicenter phase II trial. Lung Cancer 56 (2007) 371-376
28. Santo A., Genestreti G., Terzi A., Azzoni P., Sava T., Manno P., et al. Gemcitabine (GEM) and vindesine (VDS) in advanced non-small cell lung cancer (NSCLC): a phase II study in elderly or poor performance status patients. Lung Cancer 53 (2006) 355-360
29. Kudoh S., Takeda K., Nakagawa K., Takada M., Katakami N., Matsui K., et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 24 (2006) 3657-3663
30. Gridelli C., Maione P., Illiano A., Piantedosi F.V., Favaretto A., Bearz A., et al. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non-small-lung cancer: the MILES-2P studies. J Clin Oncol 25 (2007) 4663-4669
31. Frasci G., Lorusso V., Panzza N., Comella P., Nicollela G., Bianco A., et al. gemcitabine plus vinorelbine yield better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer 34 (2001) 65069
32. Hainsworth J., Spigel D., Farley C., Shipley D.L., Bearden J.D., Gandhi J., et al. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced non-small cell lung cancer. Cancer 110 9 (2007 Nov. 1) 2027-2034
33. Tibaldi C., Vasile E., Antonuzzo A., DiMarsico R., Fabbri A., Innocenti F., et al. First line chemotherapy with planned sequential administration gemcitabine followed by docetaxel in elderly advanced non-small cell lung cancer patients: a multicenter phase II study. Br J Cancer 98 (2008) 558-563
34. Jackman D.M., Yeap B.Y., Lindeman N.I., Fidias P., Rabin M.S., Temel J., et al. Phase II clinical trial of chemotherapy-naive patients > or =70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 25 (2007) 760-766
35. Gridelli C. Elderly lung cancer patients: what treatment strategies?. Expert Rev Anticancer Ther 7 10 (2007) 1331-1334
36. Balducci L. Geriatric oncology: challenges for the new century. Eur J Cancer 36 14 (2000) 1741-1754
37. Extermann M., Aapro M.S., Bernabei R., Cohen H.J., Droz J.P., Lichtman S., et al. Use of comprehensive assessment in older cancer patients: recommendations from the task force on GCA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55 (2005) 241-252
38. Charlson M., Szatrowski T.P., Peterson J., and Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 47 (1994) 1245-1251
39. LeCaer H., Fournel P., Jullian H., Chouaid C., Letreut J., Thomas P., et al. An open multicenter phase II trial of docetaxel-gemcitabine in Charlson score and performance status selected elderly patients with stage IIIB-IV non-small-cell lung cancer: the GFRC 02-02a study. Crit Rev Oncol Hematol 64 1 (2007 Oct) 73-81